14:00 - 17:00
主持人 Moderator
- 谭国超, 华安证券研究所副所长、医药首席分析师
- TAN Guochao, Deputy Director & Chief Analyst of Pharmaceutical Industry of Huaan Securities Research Institute
14:00 - 14:20
- 主题报告
- Keynote Speech
- 中国医药创新评估体系构建和探索
- China Pharmaceutical Innovation Evaluation Framework and Exploration
- 李源培, 赛麦德咨询公司亚太区准入和创新证据负责人
- Ryan LI, Asia Head of MA & Evidence Generation of SAI MedPartners
14:20 - 14:40
- 项目1
- Project 1
- 基于暂时连接技术（TransCon）的内分泌领域创新产品
- Innovative Endocrinology Solutions Powered by TransCon Technology
- 卢安邦, 维昇药业（上海）有限公司执行董事兼CEO
- Pony LU, Executive Director & CEO, VISEN Pharmaceuticals
14:40 - 15:00
- 项目2
- Project 2
- 创新驱动发展：基石药业管线2.0介绍
- Innovation-Driven Growth: CStone's Pipeline 2.0 Introduction
- 倪维聪, 基石药业首席财务官
- Nicky NI, CFO, CStone Pharmaceuticals
15:00 - 15:20
- 项目3
- Project 3
- 让创新生物药触手可及
- Making Innovative Biopharmaceuticals Reachable
- 何翔, 三生制药集团首席财务官
- Tony HE, CFO, 3SBio Inc.
15:20 - 15:40
- 项目4
- Project 4
- 百奥赛图：链接全球伙伴，共筑创新药新未来
- Biocytogen: Together with Global Partners, Shaping the Future of Innovative Therapies
- 王永亮, 百奥赛图（北京）医药科技股份有限公司副总经理兼董事会秘书
- WANG Yongliang, Deputy General Manager & Board Secretary, Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
15:40 - 16:00
- 项目5
- Project 5
- 加科思KRAS通路管线开发策略
- The Development Strategy of KRAS Pathway
- 王宜, 加科思药业首席医学官兼全球研发负责人
- Andrea WANG-GILLAM, Chief Medical Officer and Global Head of R&D, Jacobio Pharma
16:00 - 16:20
- 项目6
- Project 6
- Tag辅助多肽合成技术的应用研究
- Research on the Application of Tag-Assisted Peptide Synthesis Technology
- 徐峰, 浙江九洲药业股份有限公司TIDES中国区负责人
- XU Feng, Head of TIDES China, Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
16:20 - 16:40
- 项目7
- Project 7
- 恒瑞医药：根植中国、全球领先的创新型制药企业
- Hengrui Pharma: A Leading Innovative Global Pharmaceutical Company Rooted In China
- 刘笑含, 江苏恒瑞医药股份有限公司董事会秘书
- LIU Xiaohan, Board Secretary, Jiangsu Hengrui Pharmaceuticals Co., Ltd.
16:40 - 17:00
- 项目8
- Project 8
- 药明巨诺：以创新为先导，成为细胞免疫治疗引领者
- JW Therapeutics: Become An Innovation Leader in Cell Immunotherapy
- 林庄微, 上海药明巨诺生物科技有限公司高级总监
- Vivian LIN, Senior Director, JW Therapeutics (Shanghai) Co., Ltd.
会议咨询